[Federal Register Volume 80, Number 129 (Tuesday, July 7, 2015)]
[Notices]
[Page 38714]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-16500]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Treatment of Acute and 
Chronic Neurological Injuries Involving Axonal Regeneration

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an exclusive patent 
license to practice the following inventions embodied in the following 
patent applications:

HHS Ref. No.: E-214-2012/0
Titled: ``Compositions and Methods for the Treatment of Central 
Nervous System Injury''
    1. US Provisional Patent Application No.: 61/705,555 HHS Ref. 
No.: E-214-2012/0-US-01 Filing Date: September 25, 2012
    2. PCT Patent Application No.: PCT/US2013/061693 HHS Ref. No.: 
E-214-2012/0-PCT-02 Filing Date: September 25, 2013
    3. Australian Patent Application No.: 2013-32367 HHS Ref No.: E-
214-2012/0-AU-03 Filing Date: September 25, 2013
    4. European Patent Application No.: 13771750 HHS Ref. No.: E-
214-2012/0-EP-04 Filing Date: September 25, 2013
    5. U.S. Patent Application No.: 14/430,850 HHS Ref. No.: E-214-
2012/0-US-06 Filing Date: September 25, 2013

to BioAxone Biosciences Incorporated (``BioAxone''), a company 
incorporated under the laws of the State of Delaware having an office 
in at least Cambridge, Massachusetts, U.S.A. The patent rights in these 
inventions have been assigned to the United States of America. BioAxone 
is seeking all worldwide territories for this license. The field of use 
may be limited to ``Treatment of human acute and chronic neurological 
injuries involving axonal regeneration, as monotherapy or in 
combination with other therapeutic drugs or medical devices''.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
August 6, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, patents, 
inquiries, comments, and other materials relating to the contemplated 
exclusive license should be directed to: Cristina Thalhammer-Reyero, 
Ph.D., M.B.A., Office of Technology Transfer, National Institutes of 
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 435-4507; Facsimile: (301) 402-0220; Email: 
[email protected]. A signed confidentiality nondisclosure agreement 
will be required to receive copies of any patent applications or 
patents that have not been published or issued by the United States 
Patent and Trademark Office or the World Intellectual Property 
Organization.

SUPPLEMENTARY INFORMATION: This technology, and its corresponding 
patent applications, is directed to methods of treating or preventing 
spinal cord injury or a glial scar by administering an agent that 
reduces the amount or activity of a 4-sulfacted GalNAc in a chondroitin 
glycosaminoglycan chain, wherein said agent includes human enzyme, 
arylsulfatase B (ARSB). This technology, and its corresponding patent 
applications, is also directed to methods of increasing neuron growth, 
proliferation, or migration by administering an agent that reduces the 
amount or activity of a 4-sulfacted GalNAc in a chondroitin 
glycosaminoglycan chain, wherein said agent includes ARSB. This 
technology may be useful as a means to treat paralysis and motor 
defects induced by spinal cord injury, such as by promoting axonal 
regrowth.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404. The prospective exclusive license may be granted unless within 
thirty (30) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.
    Properly filed competing applications for a license in response to 
this notice will be treated as objections to the contemplated license. 
Comments and objections submitted in response to this notice will not 
be made available for public inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: June 30, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-16500 Filed 7-6-15; 8:45 am]
BILLING CODE 4140-01-P